These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34748673)

  • 1. Risankizumab-induced paradoxical pustular psoriasis.
    McFeely O; Pender E; Victory L; Almutlaq H; Storan E
    Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab for the treatment of psoriasis.
    Gu C; Yang J
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
    [No Abstract]   [Full Text] [Related]  

  • 4. A drug safety evaluation of risankizumab for psoriasis.
    Huang YW; Tsai TF
    Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
    [No Abstract]   [Full Text] [Related]  

  • 5. Risankizumab in moderate-to-severe plaque psoriasis.
    Serrano L; Maloney V; Gordon KB
    Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generalized pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo-plantar pustulosis.
    De Silva BD; Benton EC; Tidman MJ
    Clin Exp Dermatol; 1999 Jan; 24(1):10-3. PubMed ID: 10233640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab-induced paradoxical pustular psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Clin Exp Dermatol; 2019 Jan; 44(1):72-73. PubMed ID: 30129214
    [No Abstract]   [Full Text] [Related]  

  • 11. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
    Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
    [No Abstract]   [Full Text] [Related]  

  • 12. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
    McDonald J; Maliyar K; Gooderham MJ
    Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
    Paton DM
    Drugs Today (Barc); 2019 Oct; 55(10):605-613. PubMed ID: 31720558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Li W; Ghamrawi R; Haidari W; Feldman SR
    Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
    J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of von Zumbusch generalized pustular psoriasis with cyclosporine after eruption post etanercept injection.
    Ephrem G; Jour G; Smith BL
    J Med Liban; 2011; 59(3):168-9. PubMed ID: 22259908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
    Torres T
    Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
    Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
    J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
    Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
    J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.